


Grab and Go!

ADMINISTRATION IS COMPLETE IN 3 SIMPLE STEPS

Position



- Position between thumb and middle finger, **keeping index finger free**¹

Pierce



- **Lightly pierce skin** perpendicular to the deltoid region¹

Press




- **Gently press plunger** to inject vaccine; stop when you feel resistance¹

Activate Needle Shield and Dispose




- **Remove microneedle from skin** and direct it away from you and others¹
- **Push very firmly with thumb** on plunger to **activate needle shield**.¹ Dispose of device in sharps container.


WHAT MANY PATIENTS EXPERIENCE



Example 1:
Bump with no redness



Example 2:
Redness without a bump



Example 3:
Redness with a bump

Illustrations are for visual reference only. Injection-site reactions can vary for each patient.

Talk to your patients about the reactions they might experience, such as a **raised bump, redness, swelling, pain, and itching**, and assure them that reactions generally resolve on their own in **3 to 7 days**.²

Please [click here](#) for Important Safety Information.

Fluzone[®]
intradermal
QUADRIVALENT
INFLUENZA VACCINE
Small. Simple. Smart.

IMPORTANT SAFETY INFORMATION

INDICATION

Fluzone Intradermal Quadrivalent vaccine is indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Fluzone Intradermal Quadrivalent vaccine is approved for use in persons 18 through 64 years of age.

SAFETY INFORMATION

The most common local reactions to Fluzone Intradermal Quadrivalent vaccine include pruritus, erythema, swelling, and induration at the injection site. Such reactions occurred more frequently with trivalent Fluzone Intradermal vaccine than with trivalent Fluzone vaccine. Other adverse reactions to Fluzone Intradermal Quadrivalent vaccine include pain at the injection site; myalgia, headache, and malaise. Other adverse reactions may occur.

Fluzone Intradermal Quadrivalent vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Intradermal Quadrivalent vaccine should be based on careful consideration of the potential benefits and risks. Vaccination with Fluzone Intradermal Quadrivalent vaccine may not protect all individuals.

Before administering Fluzone Intradermal Quadrivalent vaccine, please [click here](#) for full Prescribing Information.

To order Fluzone Intradermal Quadrivalent vaccine or to learn about the Fluzone Partners Program, please log onto VaccineShopper.com[®] or call **1-800-VACCINE** (1-800-822-2463).

CPT^{®a} Code: 90630

^a CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

Fluzone Intradermal Quadrivalent vaccine is manufactured and distributed by Sanofi Pasteur Inc.

References: 1. Fluzone Intradermal Quadrivalent vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2014.
2. Sanofi Pasteur Inc. Data on file (Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 through 64 Years). January 2014. MKT28928.

Fluzone[®]
intradermal
QUADRIVALENT
INFLUENZA VACCINE
Small. Simple. Smart.